Etesevimab

Summary

Etesevimab (CHEMBL4650488) is a phase-3 clinical-stage antibody; indicated across 1 condition including severe acute respiratory syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 1 condition
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650488
Name	Etesevimab
Type	Antibody
Max phase	3

Also known as: Anti-sars-cov-2 antibody js016, CB-6, CB6, Etesevimab, JS-016, JS016, LY COV016, LY-3832479, LY-COV016, Ly3832479, LY3832479, NP-005

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	CoV Spike glycoprotein	Binding

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE1	4
PHASE3	2
PHASE2	2
PHASE4	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04790786	PHASE4	TERMINATED	UPMC OPTIMISE-C19 Trial, a COVID-19 Study
NCT04427501	PHASE2/PHASE3	COMPLETED	A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
NCT04497987	PHASE3	COMPLETED	A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
NCT05205759	PHASE3	TERMINATED	Non-inferiority Trial on Monoclonal Antibodies in COVID-19
NCT04634409	PHASE2	COMPLETED	A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
NCT04931238	PHASE2	UNKNOWN	Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19)
NCT04441918	PHASE1	UNKNOWN	Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects
NCT04441931	PHASE1	COMPLETED	A Study of LY3832479 (LY-CoV016) in Healthy Participants
NCT04611789	PHASE1	COMPLETED	A Study of LY3832479 (LY-CoV016) in Healthy Participants 1
NCT05167279	PHASE1	COMPLETED	A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).